Branded vs. compounded GLP-1s: what the evidence says
Quick answer
The creator addresses patients transitioning from FDA-approved GLP-1 receptor agonists to compounded alternatives, correctly noting the absence of formal comparative efficacy data and the importance of pharmacy quality verification. The most clinically significant gap in the video is the omission of the salt-form issue, where compounded semaglutide products often use sodium or acetate salts rather than the base form approved in branded drugs, a distinction the FDA has flagged in safety communications. Patients switching formulations should be monitored by a clinician using objective markers like weight trajectory, not solely subjective appetite assessment.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @drrekhakumar actually say?
The creator, who identifies as an endocrinologist, walked through what patients should watch for when switching from a branded GLP-1 (like Ozempic or Wegovy) to a compounded version. The core points: compounded GLP-1s are not FDA-approved, there are no formal comparative efficacy studies, potency may differ, and patients should verify that their compounding pharmacy does third-party testing. She specifically told viewers to ask, "do they test for potency?" and to monitor whether they feel "the same as you did on your branded." This is practical, patient-facing guidance, not a deep pharmacology lecture. Worth noting: she did not claim compounded versions are equivalent, and she did not recommend any specific product or dose. That restraint matters in this space.
Does the science back this up?
On the FDA status and lack of comparative studies, she is correct. The evidence on compounded semaglutide or tirzepatide efficacy is essentially nonexistent in peer-reviewed literature. The branded drugs earned their approvals through large, controlled trials, including the SUSTAIN and STEP programs for semaglutide and the SURMOUNT trials for tirzepatide. No equivalent trials exist for compounded versions.
The concern about potency is legitimate but more complex than the video conveys. A 2023 analysis by the FDA flagged multiple compounding pharmacies producing semaglutide products with inaccurate dosing, impurities, or incorrect salt forms (the base vs. acetate vs. sodium salt issue). The American Society of Health-System Pharmacists has also raised concerns about variability in compounded injectable peptides. Third-party testing is a real and meaningful safeguard, and it is genuinely underused in this market. Her suggestion to ask pharmacies directly about testing protocols is sound, practical advice.
What did they get wrong (or right)?
She got the headline right: compounded GLP-1s carry real unknowns, and the absence of FDA approval means there is no guaranteed standardization of potency, sterility, or stability. That is not a scare tactic. It is the regulatory reality.
Where the video falls short is the framing around "active pharmaceutical ingredients." She says, "being that we don't know about some of the active pharmaceutical ingredients of the compounded versions." This is a bit muddled. The active ingredient in compounded semaglutide is, in most cases, semaglutide, but the issue is the salt form. The FDA has specifically warned that semaglutide sodium and semaglutide acetate are not the same as semaglutide base, the form used in Ozempic and Wegovy. This distinction is clinically meaningful and was omitted. A 2024 FDA safety communication noted adverse event reports linked to compounded semaglutide products, some tied to dosing errors or incorrect formulations.
She also frames potency monitoring entirely around subjective appetite control, which is reasonable but incomplete. Patients could feel similar appetite suppression at a lower dose due to adaptation, not equivalent potency. Objective monitoring, like weight trajectory, would strengthen that guidance.
What should you actually know?
If you are considering or already using a compounded GLP-1, here is what the evidence actually supports. The FDA removed semaglutide from its drug shortage list in 2024, which legally restricts most compounding pharmacies from producing copies of FDA-approved drugs like Ozempic and Wegovy under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. That regulatory landscape is shifting fast, and access to compounded versions may change depending on legal challenges and shortage designations.
Third-party testing is not optional if you are using a compounded injectable. Ask specifically whether the pharmacy tests for:
- Potency (is the labeled dose what is actually in the vial)
- Sterility (injectable products carry infection risk if improperly prepared)
- Absence of impurities or degradation products
The creator's suggestion to call the pharmacy directly is a low-bar but real first step. PCAB (Pharmacy Compounding Accreditation Board) accreditation is another marker worth asking about. Finally, talk to your prescribing provider before switching, not after. This video is useful context, but it is not a substitute for a clinical conversation about your specific situation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Branded vs. compounded GLP-1s: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Branded vs. compounded GLP-1s: what the evidence says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator addresses patients transitioning from FDA-approved GLP-1 receptor agonists to compounded alternatives, correctly noting the absence of formal comparative efficacy data and the importance of pharmacy quality verification.
FormBlends verdict
The creator addresses patients transitioning from FDA-approved GLP-1 receptor agonists to compounded alternatives, correctly noting the absence of formal comparative efficacy data and the importance of pharmacy quality verification. The most clinically significant gap in the video is the omission of the salt-form issue, where compounded semaglutide products often use sodium or acetate salts rather than the base form approved in branded drugs, a distinction the FDA has flagged in safety communications. Patients switching formulations should be monitored by a clinician using objective markers like weight trajectory, not solely subjective appetite assessment.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator addresses patients transitioning from FDA-approved GLP-1 receptor agonists to compounded alternatives, correctly noting the absence of formal comparative efficacy data and the importance of pharmacy quality verification. The most clinically significant gap in the video is the omission of the salt-form issue, where compounded semaglutide products often use sodium or acetate salts rather than the base form approved in branded drugs, a distinction the FDA has flagged in safety communications. Patients switching formulations should be monitored by a clinician using objective markers like weight trajectory, not solely subjective appetite assessment.
- The FDA removed semaglutide from its drug shortage list in 2024, which legally restricts most 503A and 503B compounding pharmacies from producing compounded copies of Ozempic and Wegovy under federal law.
- A 2024 FDA safety communication documented adverse events linked to compounded semaglutide, including dosing errors and incorrect salt forms (sodium and acetate vs. the approved base form used in branded products).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The FDA removed semaglutide from its drug shortage list in 2024, which legally restricts most 503A and 503B compounding pharmacies from producing compounded copies of Ozempic and Wegovy under federal law.
- A 2024 FDA safety communication documented adverse events linked to compounded semaglutide, including dosing errors and incorrect salt forms (sodium and acetate vs. the approved base form used in branded products).
- No peer-reviewed randomized controlled trials have compared the efficacy or safety of compounded semaglutide or tirzepatide to their FDA-approved counterparts as of mid-2024.
- Third-party testing for potency and sterility is a meaningful but voluntary safeguard. Asking pharmacies whether they hold PCAB accreditation is a more standardized quality check than asking about testing alone.
- Subjective appetite monitoring is a reasonable but incomplete way to assess compounded GLP-1 potency. Weight change tracked over 4 to 8 weeks provides more objective evidence of whether a product is working.
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean weight loss with branded semaglutide 2.4mg. There is no comparable published data for any compounded version.
- Patients should discuss any planned switch from branded to compounded GLP-1s with their prescribing provider before making the change, not after, since formulation differences may require dose adjustments.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Rekha Kumar · TikTok creator
4.8K views on this video
Replying to @wrina I’ve been getting a lot of questions about what to look out for if you’re switching from branded to compounded GLP-1s — here’s what I tell my patients 🩺✔️ #doctok #doctor #doctorsoftiktok #obesitymedicine #obesitydoctor #obesity #endocrinologist #weightloss #weightlossjourney #weightlossmedication #weightlossgoals #weightcare
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Rekha Kumar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.